Oscar Health: Undervalued, But Not Without Risk

Oscar Health (OSCR) reported Q2 earnings in line with preliminary results, which contributed to a recent share price rebound, though the stock is still considered deeply undervalued. The company faces significant near-term uncertainty due to ACA-specific risks, including subsidy expiration, adverse selection, and new legislation, which could threaten enrollment and profitability, making it more vulnerable than diversified competitors. Despite these headwinds, Oscar is viewed as uniquely positioned for long-term growth, particularly if ICHRA adoption improves the ACA risk pool.

Analysis

Oscar Health (OSCR) reported second-quarter earnings that aligned with its preliminary results, sparking a rebound in its stock price from recent lows. Despite this recovery, the company is characterized as being deeply undervalued while simultaneously facing significant short-term uncertainty. The primary headwinds are regulatory and specific to the Affordable Care Act (ACA) marketplace, including the potential expiration of subsidies, risks of adverse selection, and the impact of new legislation, all of which could negatively affect enrollment and profitability. This concentrated exposure makes Oscar Health more vulnerable to policy shifts than its more diversified competitors. Conversely, the long-term outlook is presented as potentially strong, with the company viewed as uniquely positioned for growth. This optimistic case is largely contingent on the broader adoption of Individual Coverage Health Reimbursement Arrangements (ICHRA), which could materially improve the quality of the ACA risk pool and benefit Oscar's model.

Key Decisions for Investors

• Given the high-risk, high-reward profile, investors could consider initiating a small speculative position to capture potential long-term upside, with the understanding that the investment thesis is heavily dependent on future regulatory clarity.
• Closely monitor legislative developments concerning ACA subsidies and track the adoption rate of ICHRA, as these factors are the primary drivers of Oscar Health's near-term risk and long-term growth prospects.
• For investors with a lower risk tolerance, it may be prudent to await more definitive information on 2026 enrollment or consider safer, more diversified healthcare sector alternatives that are less exposed to concentrated regulatory risk.